

Resource Summary Report

Generated by [dkNET](#) on Sep 5, 2026

AMO1

RRID:CVCL_1806

Type: Cell Line

Proper Citation

RRID:CVCL_1806

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1806

Proper Citation: RRID:CVCL_1806

Description: Cell line AMO1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Plasma cell myeloma

Defining Citation: [PMID:8426482](#), [PMID:9738977](#), [PMID:10936422](#), [PMID:11429052](#), [PMID:12886255](#), [PMID:15215163](#), [PMID:17171682](#), [PMID:18700954](#), [PMID:19306352](#), [PMID:21173094](#), [PMID:22460905](#), [PMID:25485619](#), [PMID:25688540](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:30285677](#), [PMID:30545397](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:32123307](#), [PMID:35839778](#)

Comments: Miscellaneous: HLA typing from personal communication of Pellat-Deceunynck, Catherine., Characteristics: Produces IgA kappa., Population: Japanese., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: AMO1

Synonyms: AMo1, AMO-1

Cross References: CLO:CLO_0037047, EFO:EFO_0006534, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-TABM-1088, BioSample:SAMN03472930, BioSample:SAMN03473529,

BioSample:SAMN10989573, cancercellines:CVCL_1806, CCRID:1101HUM-PUMC000683, Cell_Model_Passport:SIDM00993, CGH-DB:9156-4, ChEMBL-Cells:ChEMBL4523527, ChEMBL-Targets:ChEMBL4523558, Cosmic:1483074, Cosmic:1889514, Cosmic:2131561, Cosmic:2391800, Cosmic:2809758, Cosmic-CLP:1295741, DepMap:ACH-000838, DSMZ:ACC-538, DSMZCellDive:ACC-538, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:1295741, GEO:GSM143353, GEO:GSM290285, GEO:GSM562822, GEO:GSM886868, GEO:GSM887933, GEO:GSM1374392, GEO:GSM1669599, IARC_TP53:28503, IBRC:C10685, LiGeA:CCLE_604, LINCS_LDP:LCL-1539, PharmacDB:AMO1_62_2019, PRIDE:PXD030304, Progenetix:CVCL_1806, PubChem_Cell_line:CVCL_1806, Wikidata:Q54749810

ID: CVCL_1806

Record Creation Time: 20220427T215219+0000

Record Last Update: 20260905T184638+0000

Ratings and Alerts

No rating or validation information has been found for AMO1.

No alerts have been found for AMO1.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 15 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Tiwari PK, et al. (2026) An orally active dual CBP/p300 degrader targets core dependencies of multiple myeloma. Cell reports, 45(6), 117464.

Fulciniti M, et al. (2026) ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3. Blood cancer discovery, 7(1), 129.

Ng HL, et al. (2026) BCR::ABL1-Induced Enhancer Reprogramming Uncovers Hypersensitivity of Ph+B-ALL Cells to Enhancer-Targeting Drugs. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(25), e17231.

Shen Y, et al. (2026) comBO: A combined human bone and lympho-myeloid bone marrow organoid for preclinical modeling of hematopoietic disorders. Cell stem cell, 33(3), 421.

Tang K, et al. (2026) Targeting PRKCN, an Essential Driver Orchestrating mTOR-IRF4 Axis Independently of Kinase Activity, in Multiple Myeloma. Advanced science (Weinheim,

Baden-Wurttemberg, Germany), 13(21), e18975.

Piri R, et al. (2025) MLN0905, a new inhibitor of Polo-like kinase 1 (PLK1), enhances the efficiency of lenalidomide in promoting the apoptosis of multiple myeloma cell lines. *Investigational new drugs*, 43(2), 348.

Xu J, et al. (2025) IGF2BP1 promotes multiple myeloma with chromosome 1q gain via increasing CDC5L expression in an m6A-dependent manner. *Genes & diseases*, 12(1), 101214.

Nardone C, et al. (2025) Structural basis for the midnolin-proteasome pathway and its role in suppressing myeloma. *Molecular cell*, 85(13), 2597.

Oikonomidi I, et al. (2025) Interferon regulatory factor 4 mediates nonenzymatic IRE1 dependency in multiple myeloma cells. *PLoS biology*, 23(4), e3003096.

Heredia-Guerrero SC, et al. (2024) Functional Investigation of IGF1R Mutations in Multiple Myeloma. *Cancers*, 16(11).

Dup??r??-Richer D, et al. (2024) KDM6A Regulates Immune Response Genes in Multiple Myeloma. *bioRxiv : the preprint server for biology*.

Aubry A, et al. (2023) Deneddylation of ribosomal proteins promotes synergy between MLN4924 and chemotherapy to elicit complete therapeutic responses. *Cell reports*, 42(8), 112925.

Shirasaki R, et al. (2021) Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degradors of Oncoproteins. *Cell reports*, 34(1), 108532.

Vannam R, et al. (2021) Targeted degradation of the enhancer lysine acetyltransferases CBP and p300. *Cell chemical biology*, 28(4), 503.

Mondala PK, et al. (2021) Selective antisense oligonucleotide inhibition of human IRF4 prevents malignant myeloma regeneration via cell cycle disruption. *Cell stem cell*, 28(4), 623.